Sandrine Kram

Thoughts on this? >> Flashnet, part of a major initiative to modernize 400,000 streetlights across Belgium >> Comment below! >>> lqventures.com #IoT #mhealth #AI #healthtech #industry40

1

The time is now for Belgium to join the Access Revolution - featuring Adrian van den Hoven for IGBA - International Generic and Biosimilar medicines Association #medaxes #basisgeneesmiddelen #biosimilairegeneesmiddelen #GlobalBiosimilarsWeek #GBW24 #biosimilars #biosimilar #BiosimilarsAccess #BiosimilarsAwareness #BiosimilarsValue https://lnkd.in/e2Kf9pCe

9

As the brand lead for Immunology in Belgium, a poignant reminder on World Arthritis Day of the crucial work still to be done for those with rheumatic diseases in Belgium. With over 80,000 individuals living with rheumatoid arthritis, the importance of accurate information and choice is key. Gratitude to Rheuma.be (KBVR-SRBR), ReumaNet and CLAIR for providing vital resources. Together, on #WorldArthritisDay, we can make 'Informed Choices, Better Outcomes' a reality. #WAD2024 #ReimagineMedicineTogether.

22

⭐ Right place, right people, right time, and a wonderful partnership is born ! So grateful to BVI.EU, invest.bw and UCLouvain - Université catholique de Louvain for the eagerness to come together in this TechBio venture, gathering science, venture capital, real estate and entrepreneurship.⭐ An AI-driven drug discovery venture builder is born under brand name Quantum BioVenture Studio to foster AI-first biology research approaches in drug discovery. Getting closer to taking humans as a model for humans is therapeutic target identification, the studio will act as a start-up factory leveraging the most advanced machine learning innovations on human multiomics big data. With a focus on rare diseases, and more common diseases related to them through gene regulatory networks, QBVS will work hand in hand with Louvain4Rare coordinated by Prof Olivier Devuyst and TRAIL - Trusted AI Labs co-founded by Prof Benoit Macq. Last but not least, Quantum BioVenture Studio is the first tenant, and at the same time the growth engine, of its mother initiative Quantum Biospace. 🚀 Discover the article release issued this morning in L'Echo. Thanks Olivier Gosset for the sound coverage. Michel Meers | Geoffroy Dumonceau de Bergendal | Pierre de Waha | Xavier Bocquet | Xavier Bastin | Alexia Autenne #techbio #venturestudio #drugdiscovery #ai https://lnkd.in/e68Y-q_S

234

10 Comments

Thought-provoking evening last night with fellow Archangel companies discussing AI. Introduced to the "Hype Cycle" for the first time which has got the cogs turning! What stage do you think AI is at? #AI #Technology #Innovation

22

2 Comments

📢 Alert for all my compliance connections working in life sciences industry: At GCO Global we are always proud when our subject-matter experts are on stage to share their in-depth industry knowledge and experience. It is therefore great that Andreea Crăcuț will be speaking at the virtual ETHICS Benelux Chapter Meeting on Patient Engagement in the #LifeScience industry! When you are working in compliance, patient management or meetings and events in the life sciences industry, you better make sure not to miss this! #gcoglobal #compliance #patientengagement #strategicmeetingsmanagement #lifesciences

7

💡Insights from the bio.be Annual Event!  This afternoon, I attended the Bio.Be Annual Event, which focused on next-gen vaccines and our local footprint and position in the value chain. 👉 Here are my key takeaways: 1️⃣ 𝐁𝐞𝐥𝐠𝐢𝐮𝐦’𝐬 𝐁𝐢𝐨𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐋𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩: Belgium ranks first globally in vaccine exports, even after the pandemic! 2️⃣ 𝐂𝐚𝐥𝐥 𝐟𝐨𝐫 𝐕𝐨𝐥𝐮𝐧𝐭𝐞𝐞𝐫𝐬: To continue facilitating clinical studies for vaccine development, we need more volunteers, especially to test prophylactic vaccines. 3️⃣ 𝐈𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐜𝐞 𝐨𝐟 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬: During crises or pandemics, we need to act 10x faster... and with 10x higher volumes. Preparation is crucial, but true readiness comes from strong partnerships. Trust is essential. 4️⃣ 𝐂𝐨𝐧𝐭𝐢𝐧𝐮𝐨𝐮𝐬 𝐄𝐟𝐟𝐨𝐫𝐭: As ecosystems and governments evolve, maintaining our role in the value chain requires a clear path forward that supports R&D. A big thank you to bio.be, Frédéric Druck, Tineke Van hooland, and Geoffrey Pot for the excellent organisation! #BioTech #Vaccines #Innovation

48

2 Comments

I am happy to be a speaking about collaboration, partnerships and open innovation in the life science industry on Morning Health Talks by EIT Health and DEX Innovation Centre (DEX IC) this Thursday, June 20, 2024. If you are curious about the perspectives of Roche Danmark and real life examples of partnerships and implementation of new health tech spiced up with personal experience, please do not hesitate to join the event. You can see details below! #digitalhealth #partnerships #sustainablehealthcare #futurehealth

21

3 Comments

December 5 is not just for celebrating Sinterklaas🎅... its also a day to reflect on the life sciences and the pharmaceutical industry as it continues to evolve rapidly. Join us for our new edition of "Nine for 2025" A review of 9️⃣ key issues which are new or see inflection points in 2025, transforming global life sciences, healthcare systems or the pharmaceutical industry in 2025 and beyond. The review covers macro and environmental issues affecting global life sciences and #healthcare, #innovative and #technology issues driving the Life Sciences and Pharma industries to deliver value to healthcare systems, and the critical business and competitive issues companies will face. 3 key areas of discussion: 1️⃣ After 2024’s bumper set of elections across the world, what’s on the political agenda which will impact healthcare delivery and life sciences businesses in 2025 and beyond? How can the global pharmaceutical industry address an increasingly fragmented international landscape? 2️⃣ What will be the therapeutic breakthroughs and key innovations of 2025 for the global pharmaceutical industry? What will the Obesity market, rapidly becoming one of the world’s most valuable therapeutic areas, evolve into in 2025? How will AI in healthcare and life sciences diverge and transform as regulation becomes a reality? 3️⃣ How will the race for manufacturing capacity be a critical element of public and commercial strategy in an era of supply shortages and new mass prevalence disease innovation?. How will pharma’s closer engagement with patients transform healthcare delivery and the pharmaceutical industry? What could happen to Life Sciences investment in 2025, and what are the implications? Stay ahead of the curve and register 👉https://lnkd.in/esq8zPBa Jad Khoury Adrien Decheix - Your Clinical Partner Victor Bony Fatimzahra Zahir Chris Ball Antonio Vila-Coro Christopher Lech, PhD Etienne DROUET Pierre Antoine A. Michelle M. Guillaume LAULHE Michele Cimmino Olivier Humbey Katy Phillips Hollie Gracie

41

2 Comments

🌟 Impact week 2024: Our Impact on Patients – Access at Scale 🌟 At Viatris BeLux, the impact we strive to make is clear: Empower people to live healthier at every stage of life. 🌍 Recently, we fought to ensure patients can continue having access to their essential medications at an accessible price, safeguarding their health and well-being. Each time we succeed, we’re reminded of the real lives impacted by these efforts. Together, we’re committed to a future where patients aren’t just part of a system – they’re individuals who benefit from a more affordable, equitable approach to healthcare. Every effort we put in, every barrier we break down, creates a positive impact on patients’ lives, ensuring they receive the treatments they need and deserve. #ImpactWeek #PatientImpact #ViaViatris #ViatrisBeLux

22

Last Thusday, I attended the Voka Health Community congress . The focus was on how #technology can impact #healthcare . Did you know that : - 20 procent of healthcare activity can be virtualized? - digital health reduces environmental impact (specifically on CO2 emissions) - only 3 procent of health data is used - digital development can also increase diagnosis rates for several serious chronic diseases Generating more data, increasing data usage and making these data actionable for healthcare, should be focuspoints for the future to make sure that technology serves for a better heathcare of the future. #digital #digitalhealth #nnbelux #novonordisk #data #voka #technology #voka_hc

56

Do we build, buy, borrow, bind or bot our Talent ? Again an interesting discussion #VOKAHRBOARD this morning @ the #RENEWI site in Ghent (THANKS for the warm welcome!) The blended mix of own employees, freelancers, consultants, outsourced services, robots requires a good understanding of the needed business skills and the level of skill expertise required. Where do we want to make bold decisions to grow to a more colorful blend ? How can we engage this blended workforce in the company's culture and values ? And what is needed as legal framework that ànd optimizes the blended workforce collaboration ànd protects each of the individuals in this mix ? Let's gear up these insightful dialogues between HR and the business to come to a perfect B-B-B-B-B mix ! #futuretalent #blendedworkforce

21

1 Comment

🚀 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗼𝗿𝘀: 𝗪𝗵𝗮𝘁 𝗔𝗿𝗲 𝗬𝗼𝘂𝗿 𝗕𝗶𝗴𝗴𝗲𝘀𝘁 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀? 🚀 I had a fantastic time at the 𝗯𝗲𝗠𝗲𝗱𝗧𝗲𝗰𝗵 𝗖𝗼𝗻𝗻𝗲𝗰𝘁 event with my business partner, Chris Juliam! Meeting the board of directors and discussing the future of medical devices and digital health in Belgium and the EU was insightful. Soon (by 2030), certain digital health technologies and medical devices will undergo joint clinical assessments as part of the EU Health Technology Assessment Regulation. However, the specifics of how digital health apps will be evaluated under this framework are still being refined. 𝗧𝗵𝗶𝘀 𝗺𝗮𝗱𝗲 𝗺𝗲 𝘁𝗵𝗶𝗻𝗸: 𝗪𝗵𝗮𝘁 𝗮𝗿𝗲 𝘁𝗵𝗲 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗰𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗲𝗿𝘀 𝗼𝗳 𝗱𝗶𝗴𝗶𝘁𝗮𝗹 𝗵𝗲𝗮𝗹𝘁𝗵 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝘀 𝘁𝗼𝗱𝗮𝘆, 𝗮𝗻𝗱 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹𝗹𝘆 𝗳𝗿𝗼𝗺 𝟮𝟬𝟯𝟬?   𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗖𝗼𝗺𝗽𝗹𝗲𝘅𝗶𝘁𝘆: EU reimbursement frameworks currently vary, making it challenging for digital health applications. For instance, Germany's Digital Healthcare Act (DiGA) has different criteria from those in France or the UK. The new HTA Regulation aims to harmonize these processes, reducing duplication and enhancing transparency. 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗥𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀: High clinical evidence and cost-effectiveness standards are essential. Digital health products often need extensive trials and proof of benefits, which is tough for smaller companies. Germany and France have strict clinical evidence requirements before reimbursement. The new regulation could streamline market access across the EU by allowing a single evidence submission. 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗦𝘆𝘀𝘁𝗲𝗺𝘀: Integrating digital health solutions with existing healthcare systems is complex. Many providers lack the infrastructure or expertise for new technologies. Interoperability issues can hinder digital health products from working across different platforms, a challenge not addressed by the HTA regulation. 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗮𝗻𝗱 𝗔𝗱𝗼𝗽𝘁𝗶𝗼𝗻: Limited awareness and resistance among healthcare providers and patients can slow adoption. Often, there is a lack of understanding of digital health benefits and functionalities. Education and training programs are essential to increase awareness and acceptance. 𝗞𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆: Given the challenges, it will be interesting to see if the new regulation achieves a more harmonized approach, streamlining processes, enhancing evidence requirements, and fostering greater integration and acceptance of digital health technologies. Are you looking to navigate reimbursement for medical devices or digital health technologies? We can get you started! #DigitalHealth #HealthTech #Healthcare #HTA #EU

18

5 Comments

👨‍🔬 👩‍🔬 Excited to share the new FOREUM - Foundation for Research in Rheumatology Platinum project call 2024 with UCB “Understanding pathobiology of axSpA-associated uveitis”. The grant aims at supporting the initiation of an innovative 💡 independent research project for a period of 12 months.   The specific focus of the call is to develop a deep and specific understanding of the pathobiology of axSpA-related acute anterior uveitis 👁. Research should prioritize human uveitis studies. Priority will be given to research on local mechanisms of disease, in particular the biology of causal and regulatory cytokines, cells and tissues.   For more information please visit the FOREUM website www.foreum.org #FOREUM #Research #Funding #RMD #pathobiology #axialspondyloarthritis (#axSpA) #acuteanterioruveitis (#AAU)

20

1 Comment

How can we use the ESG reporting as enabler for a broader 'Social'- sustainable HR dialogue in the organization ? Again an interesting topic within the #NextGenerationNetwork. How can we look beyond the reporting requirements on 'Social' ? There is an opportunity to set ambitions forward on our Workforce, on how we want to implement Health & Safety, on how we want to collaborate with Communities. Let's start this dialogue on a sustainable and future oriented HR strategy with the business, let's not wait until an auditor tells us to do so. Thanks AMS for facilitating this open discussion. #AMS #Socialsustainability #ESG

23

Last week I attended a fantastic Pharma Brand Planning course in Brussels led by Edouard Demeire. The course covered brand planning from insights to strategy to tactics, emphasising customer understanding for differentiated positioning and superior value delivery. For those interested, below are some of the key learnings I took away from the course! ✅ A high-quality brand plan should demonstrate patient centricity by comprehensively mapping the patient flow, quantifying patient pools, identifying adoption of the product and competitors, and uncovering key insights from the patient experience journey. ✅ Market segmentation criteria for patients, HCPs and other stakeholders should be clearly differentiating. Priority segments should be selected and addressed with differentiated tactics that meet their specific needs and pain points. ✅ Brand positioning should be based on customer perceptions of competitors and chosen to be important, unique and sustainable. Stakeholder-specific value propositions should align with the overall brand positioning. ✅ Customer-centric tactical plans identify stakeholders and desired behaviors to address CSFs. Tactics should specifically target behavioral objectives and segment-specific beliefs or pain points rather than broad objectives. ✅ Critical success factors (CSFs) should focus on a few key insights. CSFs should align with the situation analysis, brand strategy, and enable achieving the brand's goals. ✅ Performance management involves assessing tactic impact and cost, prioritising high-impact activities, and defining leading indicator KPIs/OKRs to track progress continuously. ✅ Apply design thinking to identify stakeholder pain points and improve delivered customer value through product benefits, non-product benefits and reduced costs. ✅ In summary, the overall brand planning process spans market insights, strategy and tactics. It should foster team sensitivity to change, commitment to customer centricity, and fluid resource allocation in an agile manner. #pharma #brandplanning #brandlaunch #patientsupport

24

2 Comments

If you have not spoken with Pascal Vande Gucht you are missing out. Pascal has been evolving digital strategy for Medical Affairs for years balancing the need for change management, evolving the compliance conversations, and accelerating innovation.

4

Ready to conquer EU & US compliance effortlessly?

16